Novel treatment approaches in HR+/HER2- breast cancer

Resistance to endocrine therapy in patients with hormone-receptor positive (HR+), HER2-negative breast cancer inevitably results in relapse and metastasis, leading to death. Understanding mechanisms of intrinsic and acquired resistance has been the focus of many clinical studies. Recent advances including the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and phosphoinositide 3-kinase (PI3K) inhibitors have improved progression-free survival and overall survival in these patients, however, endocrine resistance still develops in some patients. New classes of agents including oral selective estrogen receptor degraders (SERDs) and CDK7 inhibition have been explored in advanced HR+/HER2- metastatic breast cancer.

In this podcast, we hear from Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, Mario Campone, MD, PhD, Cancérologie de l’Ouest, René Gauducheau, St Herblain, France, and Charles Coombes, MD, PhD, Imperial College London, London, UK, as they discuss the latest data evaluating oral SERDs, elcacestrant and amcenestrant, as well as the CDK7 inhibitor, samuraciclib.

The Breast Cancer Podcasts on VJOncology are supported by Seagen. Seagen have no influence over the production of the content.

The post Novel treatment approaches in HR+/HER2- breast cancer appeared first on VJOncology.